- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01932424
Blood Propofol Concentrations in Children During Spinal Surgery
Comparison of Measured Versus Predicted Blood Propofol Concentrations During Total Intravenous Anaesthesia in Children Undergoing Spinal Surgery
During major spinal surgery evoked potential monitoring is performed to detect spinal cord damage. Intra-venous anaesthesia is the preferred anaesthetic technique because volatile anaesthetic agents supress the evoked potentials. Total Intra-Venous Anaesthesia (TIVA) with propofol is commonly administered as a Target Controlled Infusion (TCI). The TCI is an automated drug delivery system which administers propofol to achieve a desired blood concentration, based on an in built pharmaco-kinetic data (TCI model) derived from previous studies. The TCI model also provides a real time predicted blood concentration to facilitate the anaesthetist to adjust the target concentration of propofol.
The TCI algorithm is based on pharmaco-kinetic data derived from previous studies in a relatively small number of patients, by a "best fit" relationship between blood levels, infusion rates and other factors (such as age and weight). Several factors make it possible for a wide discrepancy between the predicted and the true blood concentrations. This difference can be higher in children compared to adults. Also blood loss and administration of large volumes of intravenous fluids can affect the blood concentrations. This study aims to identify the difference between the predicted and true blood concentrations by using Pelorus 1500, a bedside blood propofol measurement device, in children undergoing major spinal surgery under TIVA.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
London, Storbritannia, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Trust
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Children undergoing major spinal surgery under propofol TCI
- Surgery expecting to last more than 3 hours.
Exclusion Criteria:
- Major hepatic or renal disease
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Single arm
The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels.
The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models).
The dose range is usually between a target concentration of 3-8 mcg/ml.
However the anaesthetic management is not changed for the study.
The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device.
The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
|
a bedside blood propofol measurement device
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The absolute difference between the measured and predicted concentrations of propofol in micrograms per ml of blood.
Tidsramme: Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Median Performance Error (MDPE)
Tidsramme: Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
The median value of ratio between the measured and predicted concentration of propofol to the predicted concentration (Performance error) in blood.
Expressed as a percentage.
This is a measure of overall bias of the target controlled infusion.
|
Up to 5 hours during the maintenance phase of anaesthesia, to allow a maximum of 10 samples at 20 to 30 min intervals.
|
Median Absolute Performance Error (MDAPE)
Tidsramme: Up to 5 hours during the maintenance phase of anaesthesia
|
The median value of the ratio of the absolute difference (excluding the sign) between the measured and predicted concentrations to the predicted concentration (Absolute performance error) in blood.
Expressed as percentage.
This is a measure of the accuracy of the target controlled infusion.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
Wobble
Tidsramme: Up to 5 hours during the maintenance phase of anaesthesia
|
The median value of the difference between the individual performance errors and the Median Performance Error (MDPE).
This is a measure of the distribution of the performance errors around the median.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
Divergence
Tidsramme: Up to 5 hours during the maintenance phase of anaesthesia
|
The median of the regression coefficient of the performance error against time.
This is a measure of how the target controlled infusion performs with time.
|
Up to 5 hours during the maintenance phase of anaesthesia
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Michael RJ Sury, FRCA PhD, Great Ormond Street Hospital For Children NHS Foundation Trust
- Hovedetterforsker: Selvakumar Panchatsharam, MBBS FRCA, Great Ormond Street Hospital For Children NHS Foundation Trust
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 12AR04
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Pelorus 1500
-
Zynex Monitoring SolutionsWake Forest University Health SciencesFullført
-
Zynex Monitoring SolutionsFullførtSunn | BlodtapForente stater
-
Zynex Monitoring SolutionsFullført
-
Zynex Monitoring SolutionsFullført
-
Circadian Therapeutics LtdNeuroscience Trials AustraliaFullført
-
ViriomFullførtHIV-infeksjonDen russiske føderasjonen
-
University of AlbertaFullført
-
Maastricht University Medical CenterFullført
-
GlaxoSmithKlineAvsluttet
-
Gulhane School of MedicineFullførtIdiopatisk hypogonadotropisk hypogonadismeTyrkia